Form 4: Wynnefield Partners Increases Stake in LifeCore Biomedical

Wynnefield Partners Small Cap Value LP I reports acquiring additional shares of LifeCore Biomedical, Inc., increasing its beneficial ownership.

Summary

• Wynnefield Partners Small Cap Value LP I filed a Form 4 detailing changes in beneficial ownership of LifeCore Biomedical, Inc. (LFCR) common stock.
• On October 3, 2024, Wynnefield Partners acquired 122,930 shares at $4.10 per share and 169,753 shares at $4.10 per share.
• Following these transactions, Wynnefield Partners directly owns 2,095,783 shares and indirectly owns 2,607,433 shares.
• The filing also includes information on indirect beneficial ownership through Wynnefield Partners Small Cap Value, L.P., Wynnefield Small Cap Value Offshore Fund, Ltd., and Wynnefield Capital, Inc. Profit Sharing Plan.
• Nelson Obus and Joshua Landes, as managing members of Wynnefield Capital Management, LLC, and principal executive officers of Wynnefield Capital, Inc., also reported indirect beneficial ownership.
• The reporting owners disclaim beneficial ownership of the securities except to the extent of their individual pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing, so the sentiment is neutral. It simply reports transactions.

Positives

• Increased investment by Wynnefield Partners may signal confidence in LifeCore Biomedical's future prospects.

Risks

• The document does not provide insight into the rationale behind the stock purchases, so the long-term implications are unclear.

Management Comments

• Each of the Reporting Owners identified in this statement disclaims beneficial ownership of the securities described in this statement, except to the extent of their individual respective pecuniary interest in such securities.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders and significant shareholders, providing transparency to the market.

Stakeholder Impact

• The increased stake by Wynnefield Partners could be viewed positively by shareholders.

Key Dates